A novel PET imaging tracer has been developed and proven to effectively detect a common cancer gene mutation, KRAS, which is important for targeted therapy. This research, published in The Journal of Nuclear Medicine, shows that by identifying the mutation early, physicians can customize treatment plans for better outcomes. The current method of detecting the mutation involves a biopsy, which is invasive and limited by the quality of the tissue sample. Therefore, there is a need for noninvasive methods to assess the KRAS mutation status. The PET imaging tracer, 18F-PFPMD, was created based on a recently FDA-approved KRASG12C inhibitor and was found to selectively bind to the KRASG12C protein in preclinical studies. It was proven to be safe in humans and showed higher accumulation in tumors with the KRASG12C mutation. This tracer could be a valuable tool for screening the mutation status, patient selection for targeted therapy, and monitoring therapeutic response and drug resistance in cancer patients.
Tue, 19 Dec 2023 21:48:00 GMT | Mirage News